JP2023554354A5 - - Google Patents
Info
- Publication number
- JP2023554354A5 JP2023554354A5 JP2023536086A JP2023536086A JP2023554354A5 JP 2023554354 A5 JP2023554354 A5 JP 2023554354A5 JP 2023536086 A JP2023536086 A JP 2023536086A JP 2023536086 A JP2023536086 A JP 2023536086A JP 2023554354 A5 JP2023554354 A5 JP 2023554354A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- alzheimer
- disease
- patient suffering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306589 | 2020-12-16 | ||
| EP20306589.1 | 2020-12-16 | ||
| PCT/EP2021/086308 WO2022129410A1 (en) | 2020-12-16 | 2021-12-16 | Masitinib for the treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023554354A JP2023554354A (ja) | 2023-12-27 |
| JP2023554354A5 true JP2023554354A5 (enExample) | 2024-12-23 |
Family
ID=74141317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536086A Pending JP2023554354A (ja) | 2020-12-16 | 2021-12-16 | アルツハイマー病の処置のためのマシチニブ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240058328A1 (enExample) |
| EP (1) | EP4262801A1 (enExample) |
| JP (1) | JP2023554354A (enExample) |
| KR (1) | KR20230125804A (enExample) |
| CN (1) | CN116963736A (enExample) |
| AU (1) | AU2021399925A1 (enExample) |
| CA (1) | CA3201259A1 (enExample) |
| IL (1) | IL303521A (enExample) |
| MX (1) | MX2023007029A (enExample) |
| WO (1) | WO2022129410A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025113494A1 (zh) * | 2023-11-27 | 2025-06-05 | 浙江径科医药有限公司 | 多环类化合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| HRP20110709T1 (hr) | 2007-02-13 | 2011-11-30 | Ab Science | Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza |
| AR080380A1 (es) * | 2010-03-09 | 2012-04-04 | Ab Science | Tratamiento de la demencia tipo alzheimer con masitinib |
-
2021
- 2021-12-16 US US18/256,721 patent/US20240058328A1/en active Pending
- 2021-12-16 KR KR1020237023563A patent/KR20230125804A/ko active Pending
- 2021-12-16 CA CA3201259A patent/CA3201259A1/en active Pending
- 2021-12-16 JP JP2023536086A patent/JP2023554354A/ja active Pending
- 2021-12-16 CN CN202180093808.7A patent/CN116963736A/zh active Pending
- 2021-12-16 AU AU2021399925A patent/AU2021399925A1/en active Pending
- 2021-12-16 MX MX2023007029A patent/MX2023007029A/es unknown
- 2021-12-16 EP EP21839188.6A patent/EP4262801A1/en active Pending
- 2021-12-16 WO PCT/EP2021/086308 patent/WO2022129410A1/en not_active Ceased
- 2021-12-16 IL IL303521A patent/IL303521A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| KR100651110B1 (ko) | 테르비나핀을 포함하는 제약학적 조성물 및 그의 용도 | |
| CA2492081A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| CN106421793A (zh) | 用于治疗中枢介导的恶心及呕吐的组合物及方法 | |
| JP2002528502A5 (enExample) | ||
| KR20250069704A (ko) | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 | |
| JP2021502392A5 (enExample) | ||
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| GB2613460A (en) | Methods for the prophylaxis and treatment of Covid and Covid-19 | |
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| JP2023531930A5 (enExample) | ||
| RU2706001C2 (ru) | Способ для лечения болезней мотонейронов | |
| JP3792251B2 (ja) | 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用 | |
| ES2286716T3 (es) | Composicion farmaceutica de liberacion controlada y proceso para preparar la misma. | |
| JP2024531799A5 (enExample) | ||
| JP2022177119A5 (enExample) | ||
| KR20230116865A (ko) | 우울증의 치료를 위한 nr2b-nmda 수용체 nam의 투여요법 | |
| CN105919991A (zh) | 泽兰素在制备治疗抑郁症药物中的应用 | |
| JPH0251885B2 (enExample) | ||
| CA2368352A1 (en) | Method for treating neurodegeneration | |
| RU2007116726A (ru) | Применение лавандового масла для профилактики и лечения неврастении, соматических нарушений и других болезней, связанных со стрессом | |
| JP2024527715A5 (enExample) | ||
| JPH01221316A (ja) | 脳循環代謝改善剤 | |
| Miach et al. | Double‐blind cross‐over evaluation of mazindol in the treatment of obese hypertensive patients |